Inclusion Criteria:  men or women of 18 years or older that live in Greece histologically or cytologically confirmed, advanced EGFR positive non-small cell lung cancer untreated patients for advanced NSCLC patients who are expected to receive osimertinib regardless of their enrollment in the study signed written informed consent  Exclusion Criteria:  patients with cancer other than NSCLC that require treatment pretreated patients for NSCLC patients that receive or are expected to receive or have received an investigational drug/product/intervention